Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VIR

Vir Biotechnology Inc

Mar 21 • 10:13AM ET

6.78

Dollar change -0.09
Percentage change -1.35	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN SNY NVAX

| Held by: IJR VTI VB IWM VBK VXF XBI IJS IWN SPSM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.83	Insider Own	36.28%	Shs Outstand	136.96M	Perf Week	-5.21%
Market Cap	929.44M	Forward P/E	-	EPS next Y	-3.07	Insider Trans	-0.17%	Shs Float	87.38M	Perf Month	-30.84%
Income	-521.96M	PEG	-	EPS next Q	-0.84	Inst Own	51.31%	Short Float	8.89%	Perf Quarter	-7.79%
Sales	74.20M	P/S	12.53	EPS this Y	12.21%	Inst Trans	0.79%	Short Ratio	3.85	Perf Half Y	-13.11%
Book/sh	8.40	P/B	0.81	EPS next Y	8.73%	ROA	-30.85%	Short Interest	7.77M	Perf Year	-32.23%
Cash/sh	7.25	P/C	0.93	EPS next 5Y	10.12%	ROE	-38.09%	52W Range	6.56 - 14.45	Perf YTD	-7.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.74%	ROI	-42.08%	52W High	-53.10%	Beta	1.11
Dividend TTM	-	Quick Ratio	8.71	Sales past 5Y	423.44%	Gross Margin	79.24%	52W Low	3.31%	ATR (14)	0.46
Dividend Ex-Date	Nov 03, 2010	Current Ratio	8.71	EPS Y/Y TTM	16.56%	Oper. Margin	-705.31%	RSI (14)	28.00	Volatility	4.09% 6.16%
Employees	408	Debt/Eq	0.09	Sales Y/Y TTM	-13.90%	Profit Margin	-703.40%	Recom	1.56	Target Price	32.00
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	11.27%	Payout	-	Rel Volume	0.80	Prev Close	6.87
Sales Surprise	51.54%	EPS Surprise	12.86%	Sales Q/Q	-26.29%	Earnings	Feb 26 AMC	Avg Volume	2.02M	Price	6.78
SMA20	-12.75%	SMA50	-26.67%	SMA200	-21.82%	Trades		Volume	250,383	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

Today 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
09:30AM	Loading…
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
04:30PM	Loading…
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%
May-21-24 08:17AM	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 (Business Wire) +5.37%
May-13-24 07:21PM	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies (PR Newswire)
May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 09:55AM	Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet (Zacks)
May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)
Nov-30-23 06:10AM	7 Small-Cap Stocks to Buy BEFORE the Year-End Rally (InvestorPlace)
Nov-13-23 08:00AM	Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLDs The Liver Meeting 2023 (Business Wire)
Nov-10-23 08:00AM	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLDs The Liver Meeting 2023 (Business Wire) +7.99%
Nov-08-23 08:05AM	Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (Business Wire)
Nov-04-23 11:42AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:02AM	Q3 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM	Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial Results (GuruFocus.com) +5.13%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-12-23 04:05PM	Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference (GlobeNewswire) -5.98%
Oct-11-23 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Oct-05-23 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-03-23 07:59AM	Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats (GlobeNewswire)
Sep-20-23 08:00AM	Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV (GlobeNewswire)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM
SCANGOS GEORGE A	Director	Feb 24 '25	Sale	9.45	10,056	95,063	698,239	Feb 25 03:44 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 24 '25	Sale	9.45	14,168	133,936	117,901	Feb 25 03:43 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 24 '25	Sale	9.45	1,562	14,766	46,627	Feb 25 03:37 PM
De Backer Marianne	Chief Executive Officer	Feb 24 '25	Sale	9.45	16,122	152,408	849,217	Feb 25 03:36 PM
de Verneuil Vanina	EVP and General Counsel	Feb 24 '25	Sale	9.45	5,140	48,590	86,833	Feb 25 03:34 PM
George Scangos	Director	Feb 24 '25	Proposed Sale	9.45	10,056	95,063		Feb 24 08:57 PM
Brent Sabatini	Officer	Feb 24 '25	Proposed Sale	9.45	1,562	14,766		Feb 24 08:57 PM
Ann Hanly	Officer	Feb 24 '25	Proposed Sale	9.45	14,168	133,936		Feb 24 08:56 PM
Vanina de Verneuil	Officer	Feb 24 '25	Proposed Sale	9.45	5,140	48,590		Feb 24 08:40 PM
Marianne De Backer	Officer and Director	Feb 24 '25	Proposed Sale	9.45	16,122	152,408		Feb 24 08:38 PM
SCANGOS GEORGE A	Director	Feb 18 '25	Sale	9.81	10,964	107,575	708,295	Feb 19 07:11 PM
George Scangos	Director	Feb 18 '25	Proposed Sale	9.81	10,964	107,575		Feb 18 07:50 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 13 '25	Sale	9.15	1,562	14,291	28,189	Feb 14 06:41 PM
Brent Sabatini	Officer	Feb 13 '25	Proposed Sale	9.15	1,562	14,291		Feb 13 06:49 PM
SATO VICKI L	Director	Jan 08 '25	Sale	12.52	10,960	137,219	1,312,391	Jan 08 08:03 PM
VICKI LEE SATO	Director	Jan 08 '25	Proposed Sale	7.89	43,840	345,898		Jan 08 04:22 PM
de Verneuil Vanina	EVP and General Counsel	Dec 02 '24	Sale	8.22	76	625	56,973	Dec 04 03:35 PM
VANINA ALEXANDRA HUARD DE VERN	Officer	Dec 02 '24	Proposed Sale	8.22	76	625		Dec 02 05:08 PM
de Verneuil Vanina	EVP and General Counsel	Nov 06 '24	Sale	10.11	4,397	44,454	56,973	Nov 07 07:20 PM
VANINA DE VERNEUIL	Officer	Nov 06 '24	Proposed Sale	9.64	4,397	42,387		Nov 06 04:55 PM
de Verneuil Vanina	EVP and General Counsel	Nov 05 '24	Sale	9.47	2,347	22,225	61,370	Nov 05 05:51 PM
de Verneuil Vanina	EVP and General Counsel	Nov 01 '24	Sale	7.20	1,403	10,107	63,717	Nov 05 05:51 PM
VANINA DE VERNEUIL	Officer	Nov 05 '24	Proposed Sale	9.37	2,347	21,991		Nov 05 04:23 PM
Napolitano Janet	Director	Sep 09 '24	Sale	7.80	12,190	95,032	11,616	Sep 10 04:28 PM
JANET ANN NAPOLITANO	Director	Sep 09 '24	Proposed Sale	7.76	12,190	94,594		Sep 09 04:29 PM
Ramasastry Saira	Director	Jun 11 '24	Sale	10.95	4,000	43,789	14,619	Jun 12 12:21 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '24	Sale	9.46	72,995	690,365	678,457	Apr 04 04:14 PM
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069	Apr 02 08:58 PM
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492	Mar 28 12:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience